Praxis Precision Medicines, Inc. (PRAX) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है Boston, MA, United States. वर्तमान CEO हैं Marcio Silva De'Souza.
PRAX के पास है IPO तिथि 2020-10-16, 116 पूर्णकालिक कर्मचारी, पर सूचीबद्ध NASDAQ Global Select, बाजार पूंजीकरण $7.26B.
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for central nervous system disorders caused by neuronal imbalance. The company's lead candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor modulator in Phase IIa trials for major depressive disorder and perimenopausal depression, and PRAX-944, a T-type calcium channel inhibitor in Phase IIa development for essential tremor. Praxis is also advancing PRAX-562 for severe pediatric epilepsy and adult headache disorders, along with antisense oligonucleotide programs PRAX-222 and KCNT1 targeting genetic forms of epilepsy. Founded in 2015 and headquartered in Boston, Massachusetts, the company has established partnerships with RogCon Inc., Purdue Neuroscience Company, Ionis Pharmaceuticals, and The Florey Institute to support its clinical pipeline.
